| ●Round table discussion | ||
| Present Status of Clinical Trials and Supporting Systems in Three Regions (Japan, the US and Europe) | Simizu N，Ueda K，Hosoda S，et al． | 251-87 |
| ＜Materials＞ | ||
| Supporting the Medical Community in Facing the Challenge of GCP Implementation | 289-90 | |
| Disqualified/Restricted/Assurances List for Clinical Investigators (FDA) | 291-6 | |
| The Organization and Activity of “The Education Committee for Clinical Trial of New Psychotropic Drug” (ECCT) |
Yagi G，Kamishima K，Murasaki M，et al． | 297-305 |
| The Kobe Medical Industry Development Project | 307-8 | |
| ●Report | ||
| A Report of Study on the System of Clinical Trials and the Operation of Clinical Research Coordinator in the US | Shiga T，Suzuki S，Suzuki K，et al． | 309-60 |
| ●Material | ||
| The Report of the Committee on Appropriate Execution of Clinical Trials | 361-70 | |
| Impact of the New GCP Regulation on Clinical Trials in Japan −A survey of IRB chairs− | Ueda K，Fukuhara S，P.L.Glickman，et al． | 371-8 |
| Survey of the Performance for Nurse Clinical Research Coordinator | Ibe T，Tokunaga Y | 379-91 |
| Medical Statistics as Viewed from the Perspective of Value of Information | Statistical Analysis Group：Tenri Institute of Medical Research (Chief；Maetani S) | 393-407 |
| Double blind Trial of Intravenous and Subcutaneous Administrations of Recombinant Human Erythropoietin (SNB-5001) for Anemia in Hemodialysis Patients (Revised Article) |
Koshikawa S，Ota K，Asano Y，et al． | 409-32 |
| ●Instructions for authors [English] | 433-7 | |
| ●Editor's note | 439 | |